06 Nov, 2020
Beijing, Nov. 5, 2020——InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today that the company will present latest clinical data of its BTK inhibitor Orelabrutinib at the 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, 2020, which will be hold online. The study in Patients with Relapsed or Refractory Mantle Cell Lymphoma, led by Dr. Jun Zhu, and the study in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia, led by Dr. Jianyong Li, will be presented in three posters. This is the second consecutive year for InnoCare to present Orelabrutinib data at ASH.
02 Nov, 2020
Beijing, Nov. 2, 2020——InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today that the first subject had been dosed in a Phase 1 clinical trial with its second generation pan-TRK inhibitor , ICP-723, at the Sun Yat-sen University Cancer Center.
InnoCare announces clearance by the US FDA of Phase II clinical trial using orelabrutinib for the treatment of multiple sclerosis
02 Nov, 2020
Beijing, Nov. 2, 2020——InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today the Investigational New Drug (IND) clearance of its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib by the US Food and Drug Administration (FDA) for starting phase II clinical investigations in multiple sclerosis (MS) in the United States.
12 Oct, 2020
Beijing, Oct. 12, 2020——InnoCare Pharma (HKEX: 09969), a clinical stage biopharmaceutical company, announced today that the Company has appointed Dr. Manish Tandon as Vice President of Business Development, reporting to the Co-founder, Chairman and CEO, Dr. Jasmine Cui. Dr. Tandon will be responsible for the Company’s business development strategy and execution, external collaborations, licensing and M&A.
16 Sep, 2020
Beijing, Sept. 16, 2020——InnoCare Pharmaceuticals, a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for the treatment of cancer and autoimmune diseases, announced today that the company will present at the upcoming Morgan Stanley 2020 Virtual Asia Pacific Conference and ZGC Forum.
28 Jun, 2020
InnoCare Pharmaceuticals (HKEX: 09969), a leader in the fields of cancer and autoimmune diseases, today announced the first patient dosed in a Phase 2 clinical trial of ICP-192 in patients with urothelial cancer.
01 Jan, 0001
On June 28, 2020, InnoCare (Stock Code:09969-HK), a leading innovator for global biopharmaceutical drugs, is proud to announce the appointment of Mr. Xiaodong Jin as Chief Commercial Officer (CCO).
24 Apr, 2020
On April 24th of 2019, InnoCare announced the approval of their proprietary pan-FGFR inhibitor ICP-192 by the US Food and Drug Administration (FDA) for initiation of clinical investigations. ICP-192 is the second innovative drug candidate from InnoCare approved for initiation of clinical trials in the US. ICP-192 is a highly selective pan-FGFR inhibitor targeting multiple solid tumors with FGFR gene aberrations. Currently phase I/II studies are underway in China, with encouraging preliminary results on safety and tolerability. Following the IND approval, InnoCare will soon initiate clinical studies in the US for ICP-192. InnoCare will also actively explore collaboration opportunities with innovative biotech and pharmaceutical companies in these areas. “In less than one year, another innovative drug candidate from InnoCare has obtained the FDA approval for initiation of clinical investigation. This further demonstrates the profound innovation capability of InnoCare. We will continuously focus our effort on discovering and developing safe and effective therapies for the benefit of patients around the world. " Said Dr. Jasmine Cui, co-founder, Chairman, and CEO of InnoCare.